Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65.86 USD | +0.48% | +1.02% | -18.70% |
06:28pm | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
May. 02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.